---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057151"
form_type: "8-K"
ticker: null
cik: "0001843762"
company_name: "EQRx, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T14:21:30.294458+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# EQRx resets strategy, terminates two license deals, cuts 170 jobs, posts $82.6M Q1 loss

## Summary
- Terminates license agreements with CStone (sugemalimab/nofazinlimab) and Lynk (EQ121 JAK-1 inhibitor); partners regain rights outside Greater China.
- Approves restructuring: ~170 positions eliminated; estimated total restructuring costs $45M-$55M in 2023; expects annualized cash savings of at least $125M.
- Q1 2023 net loss $82.6M vs net income $20.7M in Q1 2022; cash and investments $1.3B; expects year-end cash ~$1.1B.
- Prioritizing lerociclib (CDK4/6 inhibitor) with Phase 3 trial in endometrial cancer; seeking partnerships for aumolertinib outside Greater China.
- Plans to separate early-stage immune-inflammatory programs into new subsidiary and explore its path as an independent company.

## SEC filing metadata
- accession: 0001104659-23-057151
- form_type: 8-K
- cik: 0001843762
- company_name: EQRx, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.02, 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/tm2314964d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057151
- JSON: https://secwatch.observer/filing/0001104659-23-057151.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057151.txt

## Key facts
- Earnings Releases
  EQRx, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, EQRx issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm
- Material Agreements
  EQRx, Inc. terminated Exclusive License Agreement with CStone Pharmaceuticals with CStone Pharmaceuticals valued at $150.0 million upfront non-refundable, non-creditable payment; additional potential milestone paymen (effective 2023-05-08).
  - Action: termination
  - Agreement: license
  - Counterparty: CStone Pharmaceuticals
  - Value: $150.0 million upfront non-refundable, non-creditable payment; additional potential milestone paymen
  - Effective: 2023-05-08
  source text: Item 1.02 Termination of a Material Definitive Agreement. CStone Pharmaceuticals On May 8, 2023, EQRx, Inc. (EQRx) provided written notice to CStone Pharmaceuticals (CStone) of its termination of the Exclusive License Agreement dated October 26, 2020 between EQRx and CStone (as amended, the CStone Agreement), which termination will be effective in accordance with the terms of such agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm
- Material Agreements
  EQRx, Inc. terminated Exclusive License Agreement with Lynk Pharmaceuticals with Lynk Pharmaceutical (Hangzhou) Co., Ltd. valued at Upfront non-refundable, non-creditable payment; additional potential milestone payments up to $172.0 (effective 2023-05-08).
  - Action: termination
  - Agreement: license
  - Counterparty: Lynk Pharmaceutical (Hangzhou) Co., Ltd.
  - Value: Upfront non-refundable, non-creditable payment; additional potential milestone payments up to $172.0
  - Effective: 2023-05-08
  source text: On May 8, 2023, EQRx provided written notice to Lynk Pharmaceutical (Hangzhou) Co., Ltd. (Lynk) of its termination of the Exclusive License Agreement dated April 1, 2020 between EQRx and Lynk Pharmaceuticals (as amended, the Lynk Agreement), which termination will be effective in accordance with the terms of such agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm
- Restructurings & Charges
  EQRx, Inc. announced a restructuring with charges of in the range of $45.0 million to $55.0 million (a decrease in headcount of approximately 170 positions).
  - Type: restructuring
  - Charge: in the range of $45.0 million to $55.0 million
  - Headcount: a decrease in headcount of approximately 170 positions
  source text: a result of, or that are associated with, the other May 2023 strategic decisions. Therefore, EQRx currently estimates total restructuring costs for 2023 will be in the range of $45.0 million to $55.0 million. Each departing employee of EQRx has played an integral role in EQRx’s commitment to develop and commercialize innovative medicines for some of the most
  evidence_url: https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.